'''Rolofylline''' ('''KW-3902''') is an experimental [[diuretic]] which acts as a selective [[adenosine A1 receptor]] [[Antagonist (pharmacology)|antagonist]].<ref name="pmid17936154">{{cite journal |vauthors=Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC |title=The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance |journal=J. Am. Coll. Cardiol. |volume=50 |issue=16 |pages=1551–60 |date=October 2007 |pmid=17936154 |doi=10.1016/j.jacc.2007.07.019 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)02324-8}}</ref><ref name="pmid18926433">{{cite journal | vauthors = Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM | title = The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment | journal = Journal of Cardiac Failure | volume = 14 | issue = 8 | pages = 631–40 |date=October 2008 | pmid = 18926433 | doi = 10.1016/j.cardfail.2008.08.010 | url =  }}</ref>  It was discovered at [[NovaCardia, Inc.]] which was purchased by [[Merck & Co., Inc.]] in 2007.
